We are happy to announce that we will expand our collaboration with Klinikka1 based in Helsinki. Klinikka1 has very high knowledge within genetics - we at Genomill Health are looking forward this interesting new collaboration.
As of today, Cityterveys begins providing Genomill genetic test porfolio in Finland. Effectively, our high-quality solutions, including the Color test and Serenity NIPT, are now available nationally to Finnish patients and customers without referral!
We are proud and excited to represent Guardant Health and to provide Guardant360 - the leader in liquid biopsies - in Northern Europe. Contact us for more information on this revolutionary test for advanced cancer patients!
Docrates Cancer Center has agreed to offer Color and associated genetic counseling to their customers in Finland, Nordics and Russia. The collaboration provides Genomill and Docrates a unique opportunity to make highest quality genetic testing and hereditary cancer susceptibility analysis easily available. The Color test is immediately available at Docrates Cancer Center: www.docrates.com, +358 10 773 2000.
Tom Wiklund, Chief Clinical Director at Docrates Cancer Center:
“When combined with visits to a specialist in medical genetics, the new test provides an important new service for people who have several cases of cancer in their family. The test is also suitable for patients with certain hereditary cancer. Based on the test result and the patient’s background information, a specialist in medical genetics can assess the personal risk of the tested person and, together with other specialists, evaluate the need for monitoring for early detection or other actions. The test also helps to assess whether other family members should be tested.”
Genomill services and products are now available in an increasing number of clinics in Finland. Color test and Serenity NIPT have been drawing a lot of attention and are now available for a significant proportion of Finnish population.
Please let us know if you are interested to join our expanding collaboration network, drop us a note at email@example.com to learn more!
Excitement builds as Color expands the analysis to a total of 30 genes - providing a more comprehensive hereditary cancer risk analysis!
The test now covers genes conferring risk for developing breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach and uterine cancers. Genes included on the broader panel can significantly impact an individual’s risk of these cancers. For example, an APC mutation can increase the risk of colorectal cancer in both women and men up to 70-100% by age 80.
The test cost remains the same, 399 euros. This makes the Color test not only available to everyone, but also provides unbeatable cost-effectiveness compared to any other lab.
We are proud to be working with the global leader in hereditary cancer risk analysis and will continue making genetic testing accessible!
We would like to thank all the clinicians and other medical experts meeting us during the Finnish Breast Cancer Group Meeting and the SGY Meeting on 14-15 Apr 2016!
Discussion regarding our solutions for hereditary cancer risk analysis and non-invasive prenatal screening was surprisingly active and extremely positive. We are currently working hard to provide all the interested clinicians additional information on how to take advantage of the state-of-the-art solutions made available in Finland by GenoMill and our collaborators - stay tuned for additional updates!
The Finnish Breast Cancer Group Meeting on 15 Apr 2016 in Biomedicum, Helsinki, will focus on hereditary breast cancer. GenoMill is representing Color Genomics for the most advanced and cost-effective option for hereditary breast and ovarian cancer risk analysis currently available.
Meet us for more information and to discuss exciting possibilities Color enables!